Metastatic Melanoma
Conditions
Brief summary
The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the body. This study will also demostrate how safe the combined drugs are when used to treat patients with Stage 3 or Stage 4 melanoma (metastatic melanoma), which cannot be removed by surgery.
Interventions
DRUGIpilimumab
DRUGGM-CSF
Sponsors
James Graham Brown Cancer Center
University of Louisville
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients may be entered in the study only if they meet all of the following criteria. 1. Male or female patients ≥18 years of age; 2. Patients with histological confirmed melanoma (Stage IIIC or Stage IV, American Joint Commission on Cancer); 3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2; 4. Life expectancy ≥3 months; 5. At least 1 site of radiographically measurable disease by immune-related response criteria (irRC); 6. Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing: * Absolute neutrophil count (ANC) ≥1.0 x 109/L; * Platelet count ≥50 x 109/L; * Hemoglobin ≥8 g/dL; * Serum creatinine ≤3 x upper limit of normal (ULN) * Total serum bilirubin ≤2 x ULN; * Serum aspartate transaminase (AST/SGOT) or serum alanine transaminase (ALT/SGPT) ≤2x ULN, and ≤3 x ULN if liver metastases are present. 7. Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician; 8. Pre-menopausal females and females \<2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of study drug. Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year; 9. Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures.
Exclusion criteria
* Patients will not be entered in the study for any of the following: 1. Treatment with Denileukin Diftitox within 42 days prior to the start of Ipilimumab; 2. Prior treatment with Ipilimumab; 3. Known hypersensitivity to Ipilimumab or any of its components 4. Received radiotherapy for non CNS disease within the 2 weeks prior to commencing study treatment or have not recovered from side effects of all radiation-related toxicities to Grade ≤1, except for alopecia; 5. Steroids within one week prior to initiation of Ipilimumab. 6. Pre-existing autoimmune colitis. 7. Patients with an allograft requiring immunosuppression; 8. Known positive human immunodeficiency virus (HIV) 9. Pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures; 10. Have any other uncontrolled infection or medical condition that could interfere with the conduct of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Immune-related Overall Response Rate (irORR) | assessed at baseline and at 4 weeks (±1 week) following the last administration of Ipilimumab |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ipilimumab and GM-CSF IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
Ipilimumab
GM-CSF | 26 |
| Total | 26 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 8 |
| Overall Study | Lost to Follow-up | 6 |
| Overall Study | Protocol Violation | 6 |
Baseline characteristics
| Characteristic | Ipilimumab and GM-CSF |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 8 Participants |
| Age, Categorical Between 18 and 65 years | 18 Participants |
| Age, Continuous | 58 years |
| Region of Enrollment United States | 26 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 26 |
| serious Total, serious adverse events | 0 / 26 |
Outcome results
Primary
Change in Immune-related Overall Response Rate (irORR)
Time frame: assessed at baseline and at 4 weeks (±1 week) following the last administration of Ipilimumab
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ipilimumab and GM-CSF | Change in Immune-related Overall Response Rate (irORR) | 20 participants |